Buy Mounjaro 12.5mg

 

Buy Mounjaro 12.5mg, Mounjaro is an injectable medicine used for the treatment of type 2 diabetes and weight management in adults, alongside a reduced-calorie diet and exercise.

 

Containing the drug tirzepatide, the MHRA granted approval for its use in weight loss in November 2023 after promising results in improving sugar control in adults with type 2 diabetes. Buy mounjaro in canada.

 

Tirzepatide, a GIP and GLP 1 receptor agonist, plays a role in weight loss by making patients feel fuller for longer and controlling appetite.

 

Before a drug can be sold and supplied to the public, it must first be approved by the MHRA. The MHRA tests new drugs for efficacy, safety and adverse events. The information from these studies must prove the drug is safe and effective for its intended use. If the drug’s health benefits outweigh its known risks it can be approved for use. Buy mounjaro in usa

 

Mounjaro was subjected to such studies and on 8th November 2023, was approved for weight loss and weight management in adults.Tirzepatide works on two hormone pathways. The glucose-dependent insulinotropic polypeptide (GIP) is a hormone which is released from the small intestine and stimulates insulin secretion to keep blood sugar levels low after eating, thereby improving glycaemic control. Buy mounjaro online

The presence of fatty or high-sugar food triggers the release of this hormone. Once released, however, levels of GIP quickly decline. Tirzepatide takes over, keeping the levels of GIP high so that more insulin is released.

The other pathway tirzepatide works on is the glucagon-like peptide-1 (GLP-1) pathway. GLP-1 also stimulates the release of insulin. Additionally, it also acts in the brain to make you feel fuller for longer by slowing the emptying of the stomach.

Tirzepatide is the first molecule that activates both these pathways and when compared to other weight loss medications, such as Semaglutide (Ozempic/Wegovy), it has resulted in greater weight loss.

Mounjaro is suitable for weight management, including weight loss and weight maintenance alongside a reduced-calorie diet and increased physical activity in patients:

 

With a body mass index (BMI) of 30 or above

 

With a BMI of 27 or above with at least one weight-related complication such as high blood pressure, cardiovascular disease, type 2 diabetes, dyslipidaemia, high cholesterol or obstructive sleep apnoea.

 

Mounjaro is contraindicated in patients who:

 

Are allergic to the drug or any ingredient contained within.

 

Are pregnant or breastfeeding

 

Have a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia Type 2 (MEN 2)

 

It is important to note that Mounjaro is a high-risk injectable prescription-only medicine. It can only be prescribed by a registered prescriber and supplied on a valid prescription. Your healthcare provider can provide you with tailored advice regarding suitability, what dose you should take and how you should take it.

Clinical trials have found patients using Mounjaro at the highest dose of 15mg, showed a 21 percentage change in their body weight. It was also found to improve blood sugar levels whilst also reducing the risk of low blood sugar.

 

Studies measuring weight reduction found 90% of patients who kept on using the medication maintained their lower weight. When the medication was stopped, patients regained this weight. This highlights the importance of taking Mounjaro long-term for sustained weight loss.

 

Long-term studies of its effects have not been studied and more research is needed.